Home
-
CDMO/CMO Outlook: 2026 in Bio/Pharma Outsourcing
What can CDMOs/CMOs expect in 2026? DCAT Value Chain Insights looks at the key issues shaping the market for bio/pharmaceutical outsourcing in the coming year: examines key trends, fundamentals, and the variables influencing the sector’s performance.
-
The DCAT Pulse: The Tariff Outlook & Pharma
Evolving US tariff policy is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharma companies and their suppliers. A DCAT webinar gives an executive briefing…
-
Bio/Pharma Outlook 2026: The Year Ahead
What are the key issues on the bio/pharmaceutical industry’s radar in 2026? DCAT Value Chain Insights weighs in on the key trends and developments shaping the industry in the year ahead: from manufacturing and supply lines to product innovation and new drug development.
DCAT MEMBER COMPANY COMMUNITY
-
New DCAT Member Company Alert
Welcome to the newest Member Companies in the Drug, Chemical & Associated Technologies Association (DCAT). DCAT is pleased to welcome the following companies to the DCAT Member Community. To view…
-
New Episode: Production to Prescription Podcast: 2025: The Bio/Pharma Industry’s Year in Review
Without question, evolving US tariff and trade policy was the story of the year in 2025, and how such policy will be implemented looms large. At the same time, the…
-
ICYMI: 2026 DCAT Value Chain Insights Editorial Calendar Now Available
In case you missed it, the 2026 DCAT Value Chain Insights Editorial Calendar is now available. The feature schedule for 2026 focuses on major themes impacting the business of bio/pharmaceutical…
-
ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance) news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement…
